jnj-64417184
Small moleculeexperimental
Clinical trial activity
8 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 22, 2018 (NCT03403348)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Respiratory syncytial virusINHIBITOR
Respiratory syncytial virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04453189 | Phase 1 | Jul 20, 2020 | Janssen Pharmaceutica NV |
| NCT04426357 | Phase 1 | Jul 6, 2020 | Janssen Pharmaceutica NV |
| NCT04258189 | Phase 1 | Feb 4, 2020 | Janssen Pharmaceutica NV |
| NCT04208373 | Phase 1 | Dec 24, 2019 | Janssen Pharmaceutica NV |
| NCT04121052 | Phase 1 | Oct 8, 2019 | Janssen Pharmaceutica NV |
| NCT04090086 | Phase 1 | Sep 15, 2019 | Janssen Pharmaceutica NV |
| NCT03952507 | Phase 1 | May 15, 2019 | Johnson and Johnson |
| NCT03403348 | Phase 1 | May 22, 2018 | Alios BioPharma |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 6 | 6 | 1 | 2019 |
| Alios BioPharma | For profit | 1 | 1 | 1 | 2018 |
| Johnson and Johnson | For profit | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1